Sunitinib is widely used to treat patients with advanced renal cell carcinoma; however, its influences on the prostate volume and lower urinary tract symptoms remain unclear. To investigate the influence of sunitinib on clinical findings of urinary tract, we recruited a total of 20 male patients with advanced renal cell carcinoma who are treated with sunitinib. We evaluated clinical findings during clinical visits over 24 weeks: International Prostate Symptom Score, urine flow rate, residual urine volume, serum prostate-specific antigen level and prostate volume. Residual urine and prostate volumes were significantly decreased at Week 24. The residual urine volume was especially decreased in patients with a high residual volume at baseline. No differences were observed in the International Prostate Symptom Score total score, International Prostate Symptom Score quality of life score, maximal urinary flow rate or prostate-specific antigen level. We observed a reduction in prostate volume and an improvement in urinary symptoms through relief from urinary tract obstruction during sunitinib treatment. Careful attention to urinary functions and drug dose adjustment seems to be necessary in patients with comorbid benign prostatic hyperplasia or dysuria.
INTRODUCTION
Molecular target drugs are commonly used to treat patients with metastatic renal cell carcinoma (RCC) and considered to be the standard of care (1, 2) . However, their drug-related adverse events such as influence on endocrine organ activity, hypothyroidism, impaired glucose tolerance and increased levels of amylase and lipases have been reported (3 -8) .
During our recent clinical experience, we observed an improvement in urinary function of several patients with advanced RCC who were treated with sunitinib. Moreover, we also found that the size of the thyroid and prostate, but not the size of the adrenal or pituitary glands, was reduced in some patients on autopsy after sunitinib therapy for RCC. Recently, serious adverse events of sunitinib, dysfunction of the endocrine organs including the thyroid and pancreas, have been reported (9) . However, influence of sunitinib on the prostate volume and urinary symptoms remains unclear. We examined the prostate volume and lower urinary tract symptoms in patients with advanced RCC to investigate the influence of long-term sunitinib therapy on them.
PATIENTS AND METHODS
From 2008 through 2012, we enrolled a total of 20 male patients with advanced RCC who had received sunitinib for .24 weeks. We evaluated the international Prostate Symptom Score (IPSS), urine flow rate and residual urine volume every 6 weeks, while the serum prostate-specific antigen (PSA) level and prostate volume every 12 weeks. Prostate volume was determined by transrectal ultrasonography or computed tomography (CT). Residual urine volume was determined by ultrasound imaging. The exclusion criteria were as follows: previous prostate-, rectum-, or bladder-related surgery or radiation therapy, urethral stricture or Parkinson's disease; and 5-a reductase inhibitor to treat benign prostatic hyperplasia (BPH). Patients, whose therapy with sunitinib was terminated within 24 weeks due to progressive tumor growth, were also excluded.
The characteristics of each subject are shown in Table 1 . The median age of the 20 patients was 61 years. Twelve patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0; the remaining eight patients had an ECOG PS of 1. None of the patients had ECOG PS of 2. According to the Memorial Sloan-Kettering criteria, 6 and 14 patients were at favorable and intermediate risks, respectively. None of the patients were assessed to be at poor risk. A total of 17 patients (85%) were histologically confirmed to have clear cell RCC. Most of the patients (14 of 20, 70%) received sunitinib as the first-line treatment. Metastatic sites included the lung (n ¼ 15), bone (n ¼ 6) and lymph node (n ¼ 5) ( Table 1) . Two patients had received prior a-blocker (tamsulosin) therapy due to the complication of BPH. A total of 14 patients needed dose reduction of sunitinib due to sunitinib-related adverse events.
STATISTICAL ANALYSIS
The IPSS total score and IPSS quality of life (QOL) score were compared using the Wilcoxon-signed ranks test. All other values were assessed using a paired t-test. P , 0.05 was considered statistically significant. All statistical analyses were performed using SPSS, version 11 (Japan IBM, Tokyo, Japan).
RESULTS
Changes from the baseline in prostate volume, serum PSA and lower urinary tract symptoms are summarized in Table 2 . At 24 weeks, the residual urine volume (P ¼ 0.034) and prostate volume (P ¼ 0.038) were significantly reduced from baseline. No significant differences were observed in the IPSS total score, IPSS QOL score, maximal urinary flow rate (Q max ) or PSA level over the treatment sessions. A total of 10 patients showed improvement in residual urine volume at 18 weeks. The amount of urine in seven of eight patients who had residual urine volume .50 ml at baseline decreased at 24 weeks (Fig. 1) . The prostate volume at 24 weeks was reduced in 12 patients, unchanged in five patients and slightly increased in three patients. The relative dose intensities of the 12 patients in Cycles 1 and 2 were 74.2 and 70.6%, respectively. On the other hand, the relative dose intensities of the eight patients with no reduction in prostate volume in Cycles 1 and 2 were 68.5 and 63.1%, respectively. All patients with reduction in prostate volume developed hypothyroidism.
In the context of metastatic site, partial response (PR) was achieved in five patients, and 15 patients showed stable disease (SD) with sunitinib. No association was found between the reduction of prostate volume and tumor shrinkage in metastatic lesion.
CASE REPORTS
A 64-year-old man was administered 50 mg of sunitinib daily as the first-line treatment for RCC and lung and pancreatic Jpn J Clin Oncol 2013;43 (12) 1283 metastases. Although the patient had been diagnosed with BPH, he did not choose to receive further treatment for it. At Week12 of sunitinib therapy, a CT scan confirmed that he had achieved PR and SD with regard to lung and pancreatic metastases, respectively. At Week 18, he experienced less frequent urination and the change in the total IPSS from baseline was 26. At Week 24, we confirmed that prostate volume was reduced by 55% from baseline, by CT (Fig. 2) . Although a reduction in body weight by sunitinib-related adverse effect was observed at a dose of 37.5 mg per day, he continues to receive the therapy.
DISCUSSION
Sunitinib is the standard first-line treatment for advanced RCC 1 ; however, multiple adverse events have been reported despite its effectiveness (3, 4) . Sunitinib is known to cause abnormal functioning of the thyroid and pancreas, and it has been implicated that sunitinib affects other endocrine organs (5 -8) . In autopsies of patients with advanced RCC, we found that the total weight of thyroid and total prostate was markedly reduced to 2 and 5 g, respectively, through sunitinib therapy. Tubular shrinkage and fibrosis were observed histologically in the prostatic tissue, and vascular occlusion caused by angiogenesis was found inside the microvessels (data not shown due to the limitations in the number of figures allowed). Since sunitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptor, these abnormalities seem to be caused by sunitinib treatment through damage to vascular endothelial cells and following ischemic tissue injury.
Sunitinib is a multitargeted tyrosine kinase inhibitor of VEGF receptors 1 -3 and platelet-derived growth factor (PDGF) receptors a and b (10). Since VEGF and PDGF are the most potent mitogenic factors stimulating both endothelial and epithelial cells in a normal prostate gland (11, 12) , reduction in prostate volume might be caused by the inhibition of VEGF and PDGF receptors. A recent report has shown a marked reduction in the thyroid gland by sunitinib (9,13). In our study, a reduced thyroid function was observed in all patients whose prostate volume decreased by sunitinib. Since the relative dose intensity in Cycles 1 and 2 in these patients was 70%, high-dose sunitinib may influence the volume of the prostate and thyroid glands.
It has been reported that sunitinib reduces the total prostate volume and prostatic tumor volume when administered to treat castration-resistant prostate cancer (14) . However, the effect of sunitinib on the volume of normal prostate and urinary function has not been well characterized. We here investigated how long-term sunitinib treatment for advanced RCC acts on the prostate volume and lower urinary tract symptoms.
In this study, we observed that three subjects showed a slightly increased prostate volume at 24 weeks. It has been reported that there are great differences between individuals in the area under the blood concentration time curve of sunitinib (15) . Individual variation of the blood concentration of sunitinib might influence the result. We found that urinary function was improved in 10 of 20 patients after 18 weeks from the initial administration of sunitinib. There was a tendency for patients with a high residual urine volume at baseline to improve. Prostate and residual urine volumes were reduced at Week 24, and we suspect that improvement in urinary 
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Sunitinib's influence on prostate volume obstruction due to the reduced prostate volume results in the decreased volume of residual urine. Although the prostate volume was reduced by sunitinib, no differences in IPSS total score, IPSS QOL score, or Q max were observed. Only 4 of the 20 patients had urination problems in this study. This finding may explain the reason why the statistical difference in these scores related to urinary symptoms is negligible. Of note, sunitinib improved the IPSS total score, IPSS QOL score and Q max in three-fourth patients experiencing difficulty in urinating, suggesting that sunitinib therapy is beneficial for patients with dysuria. The PSA level was not changed during the treatment, even in those patients whose prostate volume was reduced by .20%. Although further validation studies are needed, it is likely that longer-term administration of sunitinib may improve the PSA level.
Taken together, our results indicate that physicians should pay attention to urinary functions when sunitinib is administered to patients with advanced RCC complicated by BPH or dysuria. Further, it seems necessary to adjust the dosage of drugs for BPH when urinary efficiency is improved by sunitinib.
